5 - AMINO - 1Q
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels . By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg vial format.
Reconstitution Steps
Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
Draw 4.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved—solution should be clear (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Protocol Overview
Concise summary of the once‑weekly regimen.
Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
Dose Range: 2.5–5 mg once or twice daily.
Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 2.5 mg once daily to assess tolerance.
Target: 5 mg once daily or 2.5 mg twice daily (BID).
Frequency: Once or twice per day (subcutaneous).
Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
Timing: Morning administration preferred; BID dosing may be split AM/PM.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each administration; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.
How This Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT) NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.
Potential Benefits
May support reductions in fat mass while preserving lean muscle in animal models.
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies.
Enhanced grip strength observed in aged mice when combined with exercise.
Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
Long-term human safety data not established; this compound remains investigational.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise.
Prioritize sleep and stress management to support metabolic adaptation.
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols.
